Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

NCT02445976 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

197

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Seviteronel: given orally once daily in 28-day cycles

Sponsor

Innocrin Pharmaceutical

Collaborators

[object Object]
[object Object]